Mar 20, 2026
Source:
The Lancet Haematology
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial
Mar 20, 2026
Source:
The Lancet Haematology
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Mar 20, 2026
Source:
5th ITACA National Congress, Venice, Italy
Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results
Poster 267.6 KB
Mar 20, 2026
Source:
5th ITACA National Congress, Venice, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the CHAPTER-1 Open-Label Extension Study
Poster 450.9 KB
Mar 01, 2026
Source:
AAAAI 2026 Annual Meeting, Philadelphia
Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
POSTER 593.7 KB
Mar 01, 2026
Source:
AAAAI 2026 Annual Meeting, Philadelphia
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
POSTER 446.9 KB
Mar 01, 2026
Source:
AAAAI 2026 Annual Meeting, Philadelphia
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
POSTER 523.1 KB
Feb 27, 2026
Source:
AAAAI 2026 Annual Meeting, Philadelphia
A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
POSTER 424.5 KB
Feb 27, 2026
Source:
AAAAI 2026 Annual Meeting, Philadelphia
Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
POSTER 416.5 KB
Feb 27, 2026
Source:
AAAAI 2026 Annual Meeting, Philadelphia
Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
POSTER 500.3 KB
Feb 04, 2026
Source:
WSAAI 63rd Annual Scientific Session, Wailea, Hawaii
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
POSTER 221.8 KB
Dec 02, 2025
Source:
BSI-CIPN Conference 2025, Liverpool, UK
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
PRESENTATION 329.8 KB
Dec 01, 2025
Source:
BSI-CIPN Conference 2025, Liverpool, UK
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
POSTER 226.1 KB
Nov 08, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema
PRESENTATION 505.1 KB
Nov 08, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension
PRESENTATION 523 KB
Nov 07, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results
POSTER 338.8 KB
Nov 07, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results
POSTER 229.3 KB
Nov 07, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
POSTER 237.9 KB
Nov 07, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
POSTER 553.5 KB
Nov 07, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1
POSTER 660.2 KB
Nov 07, 2025
Source:
ACAAI 2025 Annual Scientific Meeting, Orlando, Florida
Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
POSTER 179.6 KB
Oct 25, 2025
Source:
2025 Japanese Society of Allergology (JSA), Tokyo, Japan
Deucrictibant vs. Standard of Care in HAE
PRESENTATION 633.8 KB
Oct 25, 2025
Source:
2025 Japanese Society of Allergology (JSA), Tokyo, Japan
Oral Deucrictibant XR Tablet for Prophylaxis of HAE Attacks: CHAPTER-3 Phase 3 Trial Design
PRESENTATION 888.3 KB
Oct 11, 2025
Source:
2025 HAEi Regional Conference EMEA, Rome, Italy
Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
PRESENTATION 563.9 KB
Oct 10, 2025
Source:
2025 HAEi Regional Conference EMEA, Rome, Italy
Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life and Disease Control in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
POSTER 551 KB
Oct 10, 2025
Source:
2025 HAEi Regional Conference EMEA, Rome, Italy
Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design
POSTER 255.5 KB
Oct 10, 2025
Source:
2025 HAEi Regional Conference EMEA, Rome, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 300.3 KB
Oct 10, 2025
Source:
2025 HAEi Regional Conference EMEA, Rome, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
POSTER 437 KB
Oct 10, 2025
Source:
2025 HAEi Regional Conference EMEA, Rome, Italy
Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
POSTER 292.2 KB
Oct 05, 2025
Source:
SIAAIC-WAO, Milan, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
POSTER 233.6 KB
Oct 05, 2025
Source:
SIAAIC-WAO, Milan, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 167.6 KB
Oct 04, 2025
Source:
DAK, Düsseldorf, Germany
Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
POSTER 1.4 MB
Oct 04, 2025
Source:
DAK, Düsseldorf, Germany
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 1.8 MB
Oct 04, 2025
Source:
DAK, Düsseldorf, Germany
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
POSTER 1.5 MB
Oct 03, 2025
Source:
SEAIC, Granada, Spain
Durability of Response to a Single Dose of Oral Deucrictibant for the On-Demand Treatment of Hereditary Angioedema Attacks
POSTER 979.3 KB
Oct 03, 2025
Source:
SIAAIC-WAO, Milan, Italy
Efficacy and Safety of Oral Deucrictibant for Prophylaxis and On-Demand Treatment of Attacks in Acquired Angioedema with C1 Inhibitor Deficiency: CREAATE Phase 3 Trial Design
POSTER 185 KB
Oct 03, 2025
Source:
SEAIC, Granada, Spain
Long-Term Safety and Efficacy of Oral Deucrictibant for the Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 1 MB
Oct 02, 2025
Source:
SEAIC, Granada, Spain
Acquired Angioedema Due to C1-Inhibitor Deficiency: Conceptual Model of Patient Experience and Assessment of Patient-Reported Outcome Measures
POSTER 334.3 KB
Sep 27, 2025
Source:
CIIC Fall 2025 Conference, Tampa, Florida, U.S.
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study and Post-hoc Analysis on Durability of Response to a Single Dose of Oral Deucrictibant
POSTER 345.5 KB
Sep 26, 2025
Source:
CIIC Fall 2025 Conference, Tampa, Florida, U.S.
Long-Term Safety, Efficacy and Sustained Therapeutic Exposure of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension and Results of a Pharmacokinetics Study in Healthy Volunteers
POSTER 1.3 MB
Aug 29, 2025
Source:
EAACI Hong Kong Allergy School 2025, Hong Kong
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylactic and On-Demand Treatment of Hereditary Angioedema Attacks: Results of the CHAPTER-1 and RAPIDe-2 Extension Trials
PRESENTATION 1.2 MB
Aug 28, 2025
Source:
EAACI Hong Kong Allergy School 2025, Hong Kong
Efficacy and Safety of Oral Deucrictibant for Prophylactic (CHAPTER-3) and for On-Demand (RAPIDe-3) Treatment of Hereditary Angioedema Attacks in Adolescents and Adults: Two Phase 3 Trial Designs
PRESENTATION 925.1 KB
Aug 09, 2025
Source:
Argentine Association of Allergy and Clinical Immunology Congress, Buenos Aires, Argentina
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
POSTER 1.2 MB
Aug 09, 2025
Source:
Argentine Association of Allergy and Clinical Immunology Congress, Buenos Aires, Argentina
RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
POSTER 1.6 MB
Jul 11, 2025
Source:
US Hereditary Angioedema Association 2025 National Summit, Baltimore, MD
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
POSTER 464.7 KB
Jul 11, 2025
Source:
US Hereditary Angioedema Association 2025 National Summit, Baltimore, MD
Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
POSTER 444.4 KB
Jul 11, 2025
Source:
US Hereditary Angioedema Association 2025 National Summit, Baltimore, MD
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
POSTER 488.1 KB
Jul 11, 2025
Source:
US Hereditary Angioedema Association 2025 National Summit, Baltimore, MD
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension
POSTER 334.3 KB
Jul 11, 2025
Source:
US Hereditary Angioedema Association 2025 National Summit, Baltimore, MD
Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
POSTER 378.1 KB
Jul 11, 2025
Source:
US Hereditary Angioedema Association 2025 National Summit, Baltimore, MD
Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
POSTER 480.5 KB
Jun 15, 2025
Source:
EAACI 2025, Glasgow, Scotland
Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone
PRESENTATION 1 MB
Jun 15, 2025
Source:
EAACI 2025, Glasgow, Scotland
Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study
POSTER 425.8 KB
Jun 15, 2025
Source:
EAACI 2025, Glasgow, Scotland
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
POSTER 331.2 KB
Jun 15, 2025
Source:
EAACI 2025, Glasgow, Scotland
Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
POSTER 279.5 KB
Jun 15, 2025
Source:
EAACI 2025, Glasgow, Scotland
Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency
POSTER 258.3 KB
Jun 14, 2025
Source:
EAACI 2025, Glasgow, Scotland
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 340.1 KB
Jun 14, 2025
Source:
EAACI 2025, Glasgow, Scotland
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
POSTER 480.8 KB
Jun 13, 2025
Source:
EAACI 2025, Glasgow, Scotland
Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema
POSTER 173.1 KB
May 31, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
PRESENTATION 529.5 KB
May 31, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
PRESENTATION 411.8 KB
May 31, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
POSTER 360.7 KB
May 31, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
POSTER 1 MB
May 31, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study
POSTER 387 KB
May 31, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Epidemiology of Bradykinin-Mediated Angioedema in the European Population
POSTER 991.1 KB
May 30, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples
PRESENTATION 622.3 KB
May 30, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
POSTER 509.5 KB
May 30, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers
POSTER 671.2 KB
May 30, 2025
Source:
The 14th C1-Inhibitor Deficiency and Angioedema Workshop, Budapest
Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures
POSTER 368.7 KB
May 30, 2025
Source:
2025 Eastern Allergy Conference (EAC), Palm Beach, Fl
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
POSTER 471.8 KB
May 30, 2025
Source:
2025 Eastern Allergy Conference (EAC), Palm Beach, Fl
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 278.3 KB
May 16, 2025
Source:
ISPOR 2025, Montreal, Canada
Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema Due to C1 Inhibitor Deficiency
POSTER 400.7 KB
Apr 04, 2025
Source:
CIIC Spring 2025 Conference, Las Vegas, Nevada
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
POSTER/PRESENTATION 1 MB
Apr 02, 2025
Source:
ACMP 2025, Houston, Texas
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 393.8 KB
Mar 30, 2025
Source:
ACMP 2025, Houston, Texas
Long-Term Safety, Efficacy and Health-Related Quality of Life of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
POSTER 473.5 KB
Mar 28, 2025
Source:
ITACA 2025, Palermo, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
POSTER 451.5 KB
Mar 28, 2025
Source:
ITACA 2025, Palermo, Italy
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
POSTER 375.4 KB
PRESENTATION 353.5 KB
Mar 08, 2025
Source:
2025 HAEi Regional Conference APAC, Manilla
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylactic and On-Demand Treatment of Hereditary Angioedema Attacks: Results of the ongoing CHAPTER-1 and RAPIDe-2 Extension Trials
Presentation 719.1 KB
Mar 07, 2025
Source:
2025 HAEi Regional Conference APAC, Manilla
Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
Poster 274.4 KB
Mar 02, 2025
Source:
AAAAI/WAO 2025, San Deigo
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
Poster 430.7 KB
Mar 02, 2025
Source:
AAAAI/WAO 2025, San Deigo
Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
Poster 229.4 KB
Mar 02, 2025
Source:
AAAAI/WAO 2025, San Deigo
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Poster 181.6 KB
Feb 09, 2025
Source:
WSAAI 2025, Waimea, HI
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
Poster 748.6 KB
Dec 15, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Poster 233 KB
Dec 15, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs Standard of Care in People Living with Hereditary Angioedema
Poster 646.2 KB
Dec 15, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: The CHAPTER-1 Open-Label Extension Study
Presentation 1.4 MB
Dec 14, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
Prophylaxis of Hereditary Angioedema Attacks With Oral Deucrictibant: Efficacy and Quality-of-Life Results from CHAPTER-1
Presentation 1.4 MB
Dec 13, 2024
Source:
APAAACI 2024, Kuala Lumpur, Malaysia
RAPIDe-2 Study: Long-term Efficacy and Safety of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks
Presentation 1.6 MB
Nov 20, 2024
Source:
ISPOR Europe 2024, Barcelona
Challenges in Identifying Information to Build Economic Evaluations in Hereditary Angioedema
Poster 225.5 KB
Nov 07, 2024
Source:
CSACI 2024, Banff, Canada
Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results
Poster 229.5 KB
Nov 07, 2024
Source:
SEAIC 2024, Bilbao, Spain
Investigating the Burden of Disease in People Living With Hereditary Angioedema and their Caregivers in Europe
Presentation 530.7 KB
Nov 07, 2024
Source:
CSACI 2024, Banff, Canada
Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results
Poster 598.5 KB
Nov 07, 2024
Source:
CSACI 2024, Banff, Canada
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 Trial
Poster 238.1 KB
Nov 07, 2024
Source:
SEAIC 2024, Bilbao, Spain
Characterizing Patient Treatment of Hereditary Angioedema Airway Attacks
Presentation 521.2 KB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study
Poster 265.2 KB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results
Poster 202.9 KB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis
Poster 182.3 KB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life
Poster 549.8 KB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans
Poster 1.1 MB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders
Poster 186.1 KB
Oct 25, 2024
Source:
ACAAI 2025, Boston, MA
Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders
Poster 232.9 KB
Oct 20, 2024
Source:
JSA 2024, Kyoto
Efficacy and Safety of Oral Deucrictibant Immediate-Release Capsule in Hereditary Angioedema: RAPIDe-3 Phase 3 Clinical Trial Design
Presentation 637.6 KB
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs. Standard of Care in People Living with Hereditary Angioedema
Poster 434.3 KB
Oct 04, 2024
Source:
BSACI 2024, Harrogate, UK
Relief and Resolution of Hereditary Angioedema Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule
Poster 626.4 KB
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Poster 285.9 KB
Presentation 1.5 MB
Oct 04, 2024
Source:
BSACI 2024, Harrogate, UK
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presentation 2.7 MB
Poster 234.4 KB
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Poster 332.1 KB
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study
Poster 678 KB
Presentation 1.4 MB
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Poster 587.5 KB
Oct 04, 2024
Source:
BSACI 2024, Harrogate, UK
Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life in Patients With Hereditary Angioedema
Poster 717 KB
Oct 04, 2024
Source:
HAEi GAF 2024, Copenhagen, Denmark
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Poster 279.6 KB
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Poster 1.2 MB
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Characterizing Use of On-Demand Treatment Among People Living With Hereditary Angioedema in Germany
Poster 469.2 KB
Sep 27, 2024
Source:
World Allergy Congress 2024, Lisbon, Portugal
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presentation 879.5 KB
Sep 27, 2024
Source:
World Allergy Congress 2024, Lisbon, Portugal
Prophylactic treatment with oral deucrictibant improves health-related quality of life in patients with hereditary angioedema
Presentation 469.2 KB
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Poster 1.6 MB
Sep 27, 2024
Source:
Deutscher Allergiekongress, Dresden, Germany
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Poster 1.2 MB
Sep 27, 2024
Source:
World Allergy Congress 2024, Lisbon, Portugal
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Presentation 735.2 KB
Sep 14, 2024
Source:
CIIC Fall 2024, Dallas, Texas, U.S.
Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Poster 734.1 KB
Sep 13, 2024
Source:
CIIC Fall 2024, Dallas, Texas, U.S.
Long-Term Safety and Efficacy of Prophylactic Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Hereditary Angioedema: Results of the CHAPTER-1 Open Label Extension Study
Poster 517.4 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders
Poster 865.3 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
A novel kinin biomarker assay for characterization of bradykinin-mediated disorders
Poster 905.1 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Deucrictibant Inhibits Carrageenan-Induced Edema in Bradykinin B2 Receptor Transgenic Rat
Poster 752.5 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
The bradykinin challenge model translates across rat, monkey and human
Poster 1.5 MB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant
Poster 765.8 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Clinical Trials Conformity with AURORA COS: a systematic literature review
Poster 139.3 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis
Poster 162 KB
Sep 06, 2024
Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results
Poster 239.2 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Treatment of HAE attacks with oral deucrictibant: RAPIDe-2 extension results
Poster 609.6 KB
Sep 06, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Long-term safety and efficacy of oral deucrictibant for HAE prophylaxis
Poster 164 KB
Sep 05, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Prophylactic Treatment With Deucrictibant Improves HAE Disease Control and HRQoL
Presentation 337.3 KB
Sep 05, 2024
Source:
Bradykinin Symposium 2024, Berlin, Germany
Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
Presentation 429 KB
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Poster 210.8 KB
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases
Poster 358.6 KB
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks
Poster 134.6 KB
Jun 02, 2024
Source:
EAACI 2024, Valencia, Spain
Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat
Poster 170.9 KB
Jun 01, 2024
Source:
EAACI 2024, Valencia, Spain
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presentation 1.5 MB
Jun 01, 2024
Source:
EAACI 2024, Valencia, Spain
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presentation 1.5 MB
Jun 01, 2024
Source:
EAC 2024, Palm Springs, FL
Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema
Poster 212.3 KB
May 22, 2024
Source:
IDDST 2024, Osaka, Japan
Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema
Presentation 1.3 MB
Apr 13, 2024
Source:
CIIC Spring 2024 Conference, Arlington, TX
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presentation 564.1 KB
Apr 13, 2024
Source:
CIIC Spring 2024 Conference, Arlington, TX
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Presentation 756.6 KB
Mar 16, 2024
Source:
3rd ITACA National Congress, Milan
Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Poster 2.5 MB
Presentation 4.8 MB
Mar 16, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presentation 1.1 MB
Mar 16, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
Presentation 622.8 KB
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Poster 2.5 MB
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Poster 356 KB
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Poster 281.3 KB
Mar 15, 2024
Source:
3rd ITACA National Congress, Milan
Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Poster 189.7 KB
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Poster 2.5 MB
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Poster 310 KB
Mar 15, 2024
Source:
2024 HAEi Regional Conference Americas, Panama City, Panama
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Poster 301.2 KB
Feb 23, 2024
Source:
2024 AAAAI Annual Meeting, Washington D.C.
Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Oral Deucrictibant in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Poster 250.9 KB
Presentation 4.5 MB
Feb 23, 2024
Source:
2024 AAAAI Annual Meeting, Washington D.C.
Understanding the Reasons not to Treat All HAE Attacks and Patient Satisfaction for on-Demand Treatment (ODT). Results from the HAE Wave II Disease Specific Program™ (DSP™) 2023.
Poster 183.7 KB
Presentation 4.5 MB
Feb 04, 2024
Source:
WSAAI Annual Meeting 2024, Koloa, Hawaii
Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Poster 264.3 KB
Feb 04, 2024
Source:
WSAAI Annual Meeting 2024, Koloa, Hawaii
Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Poster 366.6 KB
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant
Poster 949.2 KB
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results
Presentation 980.2 KB
Dec 08, 2023
Source:
GA²LEN UCARE Conference 2023, São Paulo, Brazil
Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S
Poster 359.5 KB
Nov 11, 2023
Source:
ACAAI 2023 Annual Scientific Meeting, Anaheim, CA
Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data
Poster 266.5 KB
Presentation 5 MB
Nov 10, 2023
Source:
ACAAI 2023 Annual Scientific Meeting, Anaheim, CA
Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations
Poster 207.4 KB
Presentation 7 MB
Oct 23, 2023
Source:
APAAACI 2023 International Conference, Singapore
Bradykinin B2 receptor antagonist deucrictibant immediate-release capsule for treatment of HAE attacks: Phase 2
Presentation 1.3 MB
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 4.4 MB
Oct 14, 2023
Source:
CIIC Fall 2023 Conference, Dallas, TX
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule in patients with hereditary angioedema attacks
Presentation 2.7 MB
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Presentation 395.9 KB
Sep 15, 2023
Source:
18th German Allergy Congress, Bonn, Germany
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 484.3 KB
Sep 02, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Presentation 1 MB
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary angioedema attacks: CHAPTER-1 phase 2 trial design
Poster 319.2 KB
Sep 01, 2023
Source:
HAEi Regional Conference EMEA, Munich
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Poster 1 MB
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptoms
Poster 1 MB
Jul 21, 2023
Source:
U.S. HAEA National Summit, Orlando, FL
Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial
Poster 1.8 MB
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Treatment with Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 Improves Hereditary Angioedema Attack Symptoms
Poster 1.1 MB
Jun 11, 2023
Source:
2023 EAACI Hybrid Congress, Hamberg, Germany
Efficacy and Safety of Oral Administered Bradykinin B2 Receptor Inhibitor PHVS416 in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe-1 Phase 2 Trial
Poster 700.6 KB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks
Poster 1.6 MB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema
Presentation 1.1 MB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121)
Poster 1.1 MB
May 06, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial
Presentation 870.7 KB
May 05, 2023
Source:
13th C1-inhibitor Deficiency and Angioedema Workshop, Budapest
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Poster 850.4 KB
Mar 18, 2023
Source:
2023 HAEi Regional Conference APAC, Bangkok
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presentation 920.2 KB
Feb 26, 2023
Source:
2023 AAAAI Annual Meeting, San Antonio, TX
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Poster 1.1 MB
Presentation 6.3 MB
Nov 13, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Poster 937.4 KB
Nov 12, 2022
Source:
ACAAI Annual Scientific Meeting 2022, Louisville, KY
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Poster 818.4 KB
Oct 07, 2022
Source:
2022 HAEi Global Leadership Workshop, Frankfurt
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Poster 920.1 KB
Sep 16, 2022
Source:
Bradykinin Symposium 2022, Berlin
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Presentation 926.6 KB
Jun 07, 2022
Source:
Satellite Symposium Kinin 2022
Tailored drug development for patients living with HAE
Presentation 1.6 MB
Mar 22, 2022
Source:
International Immunopharmacology
In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development
Jul 10, 2021
Source:
EAACI Annual Congress 2021, Virtual
Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAE
Poster 535.7 KB
Jun 04, 2021
Source:
12th C1-inhibitor Deficiency and Angioedema Workshop, Virtual
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Presentation 4.9 MB
Video 38.7 MB
Feb 26, 2021
Source:
2021 AAAAI Annual Meeting, Virtual
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Poster 1.9 MB
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Poster 746.5 KB
Nov 13, 2020
Source:
ACAAI Annual Scientific Meeting 2020, Virtual
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Poster 664.1 KB
Jul 30, 2020
Source:
Frontiers in Pharmacology
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Publication 1.7 MB
Apr 09, 2020
Source:
2020 AAAAI Annual Meeting, Virtual
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model
Poster 931.5 KB